No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance

Rickard E. Malmström; Magnus Settergren; Felix Böhm; John Pernow; Paul Hjemdahl

doi:10.1160/TH08-06-0385

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 101(01): 157-164
DOI: 10.1160/TH08-06-0385

Cardiovascular Biology and Cell Signalling

Schattauer GmbH

No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance

Authors

Rickard E. Malmström

¹Department of Medicine Solna, Clinical Pharmacology Unit, Karolinska Institutet and Karolinska University Hospital (Solna), Stockholm, Sweden
Magnus Settergren

²Department of Medicine Solna, Cardiology Unit, Karolinska Institutet and Karolinska University Hospital (Solna), Stockholm, Sweden
Felix Böhm

²Department of Medicine Solna, Cardiology Unit, Karolinska Institutet and Karolinska University Hospital (Solna), Stockholm, Sweden
John Pernow

²Department of Medicine Solna, Cardiology Unit, Karolinska Institutet and Karolinska University Hospital (Solna), Stockholm, Sweden
Paul Hjemdahl

¹Department of Medicine Solna, Clinical Pharmacology Unit, Karolinska Institutet and Karolinska University Hospital (Solna), Stockholm, Sweden

Abstract

Summary

In addition to lowering cholesterol, statins may reduce platelet activity and exert beneficial non-lipid (pleiotropic) effects. We evaluated the effects of two different simvastatin based treatment regimens on platelet reactivity in patients with dysglycemia and coronary artery disease (CAD). Thirty-two patients with type 2 diabetes or impaired glucose tolerance and stable CAD received six weeks of double-blind treatment with simvastatin 80 mg daily (S80; n=16) or ezetimibe 10 mg and simvastatin 10 mg daily (E10/S10; n=16). Total and low-density lipoprotein (LDL) cholesterol, and high sensitivity C-reactive protein (CRP) decreased similarly in the two groups. LDL (mM) decreased from 3.2 ± 0.6 to 1.7 ± 0.7 with E10/S10 and from 3.0 ± 1.0 to 1.4 ± 0.5 with S80 treatment. Platelet function was evaluated by whole blood flow cytometry and turbidimetric aggregometry with agonist stimulation ex vivo before and after treatment. Neither treatment affected basal or adenosine diphosphate (ADP)- or thrombin-induced platelet P-selectin expression, or fibrinogen binding, or platelet-leukocyte aggregation. Similarly, neither treatment affected ADP-induced platelet aggregation. In conclusion, lipid lowering treatment with high dose simvastatin or low dose simvastatin plus ezetimibe did not exert any substantial inhibitory effects on the basal or agonist-stimulated activity of circulating platelets in patients with stable CAD and type 2 diabetes or impaired glucose tolerance.

Keywords

Simvastatin - ezetimibe - ADP - thrombin - platelet activation

Full Text

References

References
1 Collins R, Armitage J, Parish S. et al. and the Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
2 Colhoun HM, Betteridge DJ, Durrington PN. et al. and the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
3 Heart Protection Study Collaborative Group.. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
4 Baigent C, Keech A, Kearney PM. et al. and the Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
5 Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering. Arterioscler Thromb Vasc Biol 2001; 21: 3-5.
6 Wassmann S, Laufs U, Müller K. et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300-305.
7 Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005; 25: 287-294.
8 Gaddam V, Li Y, Mehta JL. Anti-thrombotic effects of atorvastatin – an effect unrelated to lipid lowering. J Cardiovasc Pharmacol Ther 2002; 07: 247-253.
9 Bonetti PO, Lerman LO, Napoli C. et al. Statin effects beyond lipid lowering-are they clinically relevant?. Eur Heart J 2003; 24: 225-248.
10 Notarbartolo A, Davì G, Averna M. et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15: 247-251.
11 Bröijersén A, Eriksson M, Leijd B. et al. No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia. Arterioscl Thromb Vasc Biol 1997; 17: 273-278.
12 Puccetti L, Pasqui AL, Pastorelli M. et al. Time-dependent effect of statins on platelet function in hyper-cholesterolaemia. Eur J Clin Invest 2002; 32: 901-908.
13 Ridker PM, Cannon CP, Morrow D. et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Yyocardial Infarction 22 (PROVE ITTIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28.
14 Gupta EK, Ito MK. Ezetimibe: the first in a novel class of selective cholesterol-absorption inhibitors. Heart Dis 2002; 04: 399-409.
15 Gagné C, Bays HE, Weiss SR. et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 1084-1091.
16 Ferroni P, Basili S, Falco A. et al. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004; 02: 1282-1291.
17 Settergren M, Böhm F, Rydén L. et al. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J 2008; 29: 1753-1760.
18 Davidson MH, McGarry T, Bettis R. et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2125-2134.
19 Ballantyne CM, Houri J, Notarbartolo A. et al. and the Ezetimibe Study Group.. Effect of ezetimibe coad-ministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-2415.
20 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Med 1998; 15: 539-553.
21 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.
22 André P, Nannizzi-Alaimo L, Prasad SK. et al. Platelet-derived CD40L – the switch-hitting player of cardiovascular disease. Circulation 2002; 106: 806-809.
23 Hjemdahl P, Chronos N, Wilson D. et al. Epinephrine sensitizes human platelets in vivo and in vitro as studied by fibrinogen binding and P-selectin expression. Arterioscl Thromb 1994; 14: 77-84.
24 Li N, Wallén NH, Hjemdahl P. Evidence for prothrombotic effects of exercise and limited protection by aspirin. Circulation 1999; 100: 1374-1379.
25 Li N, Goodall AH, Hjemdahl P. Efficient flow cyto-metric assay for platelet-leukocyte aggregates in whole blood using fluorescence signal triggering. Cytometry 1999; 35: 154-161.
26 Born GV, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195.
27 Wallén NH, Held C, Rehnqvist N. et al. Impact of treatment with acetylsalicylic acid on the proaggrega-tory effects of adrenalin in vitro in patients with stable angina pectoris: influence of the anticoagulant. Clin Sci 1993; 85: 577-583.
28 Michelson AD, Barnard MR, Krueger LA. et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-1537.
29 Bartnik M, Rydén L, Ferrari R. et al. and the Euro Heart Survey Investigators. The prevalance of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25: 1880-1890.
30 Hu H, Li N, Yngen M. et al. Enhanced leukocyte-platelet cross-talk in type 1 diabetes mellitus: relationship to microangiopathy. J Thromb Haemost 2004; 02: 58-64.
31 Carvalho AC, Colman RW, Less RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974; 290: 434-438.
32 Serebruany VL, Miller M, Pokov AN. et al. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (From the PAR-1 inhibition by statins [PARIS] study). Am J Cardiol 2006; 97: 1332-1336.
33 Bröijersén A, Hamsten A, Eriksson M. et al. Platelet activity in vivo in hyperlipoproteinemia – importance of combined hyperlipidemia and inflammatory activity. Thromb Haemost 1998; 79: 268-275.
34 Rinder CS, Student LA, Bonan JL. et al. Aspirin does not inhibit adenosine diphosphate-induced platelet alpha-granule release. Blood 1993; 82: 505-512.
35 Li N, Hu H, Hjemdahl P. Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry. Thromb Res 2003; 111: 165-170.